Pulmonx (LUNG) general counsel sells shares, receives 150,000 RSU grant

Rhea-AI Filing Summary

Pulmonx Corp’s general counsel, David Aaron Lehman, reported multiple insider transactions in Pulmonx common stock. On March 2, 2026, he sold a total of 12,237 shares in open‑market transactions at $1.43 per share. Footnotes state these sales were made to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs) granted between March 1, 2022 and March 3, 2025, indicating they were not discretionary portfolio sales. On the same date, he received a grant of 150,000 RSUs payable solely in common stock, vesting in equal quarterly installments over four years from March 2, 2026. Following these transactions, his directly held Pulmonx shares increased to 390,755.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lehman David Aaron

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		1,163	D	$1.43	251,829	D
Common Stock	03/02/2026		S(2)		4,433	D	$1.43	247,396	D
Common Stock	03/02/2026		S(3)		2,590	D	$1.43	244,806	D
Common Stock	03/02/2026		S(4)		4,051	D	$1.43	240,755	D
Common Stock	03/02/2026		A		150,000(5)	A	$0	390,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

5. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 2, 2026.

	/s/ David Aaron Lehman	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Pulmonx (LUNG) report in this Form 4?

The Form 4 reports that Pulmonx’s general counsel, David Aaron Lehman, sold 12,237 shares of common stock at $1.43 per share and received a grant of 150,000 restricted stock units vesting over four years.

Were the Pulmonx (LUNG) insider stock sales discretionary or related to taxes?

The reported stock sales were made to cover tax withholding obligations, not as discretionary sales. Footnotes explain that the 12,237 shares were sold in connection with vesting of RSUs granted between March 1, 2022 and March 3, 2025.

How many RSUs were granted to Pulmonx (LUNG) general counsel David Aaron Lehman?

He received a grant of 150,000 restricted stock units payable solely in Pulmonx common stock. According to the disclosure, these RSUs vest in equal quarterly installments over a four‑year period starting from the grant date of March 2, 2026.

How many Pulmonx (LUNG) shares does David Aaron Lehman hold after these transactions?

After the reported sales and RSU grant, David Aaron Lehman directly holds 390,755 Pulmonx common shares. This figure reflects his updated direct ownership position as of the transactions dated March 2, 2026, according to the Form 4 data.

Does this Pulmonx (LUNG) Form 4 indicate any change in company control?

The Form 4 describes routine insider equity activity, including tax‑related share sales and an RSU grant to the general counsel. It does not indicate any change in control or major ownership shift at Pulmonx based on the disclosed figures and context.